TUBA1A
ENSG00000167552
Target class
Structural protein
Chromosome
12
Approved drugs
19
Clinical candidates (approved and in development)
83
- Approved drugs
- 19
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 83
- Chemical probe available
- No
- Target name
- TUBA1A
- Gene name
- Tubulin alpha 1a
- Gene symbol
- TUBA1A
- Protein name
- Tubulin alpha-1A chain (EC 3.6.5.-) (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin alpha-3 chain) [Cleaved into: Detyrosinated tubulin alpha-1A chain]
- TUBA3
- B-ALPHA-1
- FLJ25113
- Gene biotype
- Protein coding
- Gene family
- Tubulin alpha family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 1,761.9
- Tissue specificity (Gini)
- 0.494
- Tissue specificity (tau)
- 0.877
- KEGG gene identifiers
- hsa:7846
- Protein interaction confidence
- 0.855446
- Protein interaction partners
- 101
- R-HSA-1445148
- R-HSA-190840
- R-HSA-190861
- R-HSA-2132295
- R-HSA-2467813
- R-HSA-2500257
- R-HSA-2565942
- R-HSA-3371497
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-389957
- R-HSA-389960
- R-HSA-389977
- R-HSA-437239
- R-HSA-5610787
- R-HSA-5620912
- R-HSA-5620920
- R-HSA-5620924
- R-HSA-5626467
- R-HSA-5663220
- R-HSA-6807878
- R-HSA-6811434
- R-HSA-6811436
And 12 more, listed on the interactive page.
- End position
- 49189324
- Start position
- 49184686
- Chromosome
- 12
- Strand
- Reverse
- Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, flagellum axoneme .
- Microtubules
- Primary cilium
- Tissue specificity (tau)
- 0.876771
- Expression inequality (Gini)
- 0.493702
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)
- 1,761.9
- Brain - Hypothalamus
- 655.71
- Brain - Substantia nigra
- 642.58
- Brain - Cerebellar Hemisphere
- 562.65
- Brain - Cerebellum
- 519.91
Expression in transcripts per million
- Brain - Spinal cord (cervical c-1)1,761.9
- Brain - Hypothalamus655.71
- Brain - Substantia nigra642.58
- Brain - Cerebellar Hemisphere562.65
- Brain - Cerebellum519.91
- Colon - Sigmoid485.01
- Esophagus - Muscularis484.29
- Nerve - Tibial471.67
- Brain - Frontal Cortex (BA9)429.35
- Esophagus - Gastroesophageal Junction412.81
- Brain - Hippocampus403.41
- Brain - Nucleus accumbens (basal ganglia)383.4
- Uterus382.3
- Brain - Cortex381.89
- Brain - Anterior cingulate cortex (BA24)365.82
- Brain - Amygdala352.16
- Brain - Caudate (basal ganglia)336.03
- Brain - Putamen (basal ganglia)329.07
- Fallopian Tube289.16
- Cells - Cultured fibroblasts236.82
- Bladder218.65
- Cervix - Endocervix191.98
- Artery - Coronary191.74
- Ovary181.52
- Pituitary181.23
And 29 more, listed on the interactive page.
- GO:0007017
- GO:0030705
- GO:0051301
- GO:0005634
- GO:0005829
- GO:0005874
- GO:0005879
- GO:0005929
- GO:0015630
- GO:0036464
- GO:0055037
- GO:0070062
- GO:0005198
- GO:0005515
- GO:0042802
Related records
Trials (9,112)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (88)
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor
- Davunetide Tubulin stabiliser